- Home
- ADIL
as 07-08-2024 4:00pm EST
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CHARLOTTESVILLE |
| Market Cap: | 4.9M | IPO Year: | 2018 |
| Target Price: | $150.00 | AVG Volume (30 days): | 96.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $14.00 | Next Earning Date: | 08-19-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Adial Pharmaceuticals Inc News
ADIL Breaking Stock News: Dive into ADIL Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
Benzinga
18 days ago
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
ACCESSWIRE
a month ago
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
GlobeNewswire
a month ago
Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Benzinga
a month ago
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
GlobeNewswire
a month ago
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
GlobeNewswire
2 months ago
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Benzinga
3 months ago
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
Share on Social Networks:
Disclaimer
The information presented on this page, "ADIL Adial Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.